Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8795MR)

This product GTTS-WQ8795MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8795MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15054MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ13668MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ3917MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ11599MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ13313MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ319MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ12775MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ15303MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW